Balaxi Pharmaceuticals Ltd (BALAXI) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Balaxi Pharmaceuticals Ltd reported sales of ₹80.68 Cr, operating profit of ₹4.66 Cr (OPM 5.78%) and net profit of ₹1.3 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
BALAXI quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 77.38 73.29 76.27 70.74 56.18 72.54 70.71 80.68 Expenses 66.79 69.3 63.72 66.58 55.02 69.45 70.59 76.02 Operating Profit 10.59 3.99 12.55 4.16 1.16 3.09 0.12 4.66 OPM 13.69% 5.44% 16.45% 5.88% 2.06% 4.26% 0.17% 5.78% Other Income -4.11 3.94 -1.69 -1.78 1.59 0.1 2.92 -0.99 Interest 0.45 1.38 0.74 1.01 0.89 1.02 0.99 0.73 Depreciation 0.46 0.48 0.46 0.46 0.48 0.56 0.65 0.85 Profit before tax 5.57 6.07 9.66 0.91 1.38 1.61 1.4 2.09 Tax 17.41% 11.7% 10.56% 67.03% 84.06% 80.75% 56.43% 38.28% Net Profit 4.59 5.36 8.64 0.29 0.21 0.31 0.61 1.3 EPS in Rs 0.83 0.97 1.57 0.05 0.04 0.06 0.11 0.24
BALAXI profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 279 336 241 293 270 280 Expenses 229 279 197 260 262 271 Operating Profit 51 57 45 32 9 9 OPM 18% 17% 18% 11% 3.2% 3.2% Other Income 5 3 -38 2 3 4 Interest 1 1 3 4 4 4 Depreciation 1 2 2 2 2 3 Profit before tax 55 57 2 29 5 6 Tax 13% 19% 219% 13% 73% - Net Profit 48 46 -2 25 1 2 EPS in Rs 9.53 9.03 -0.44 4.54 0.26 0.45 Dividend Payout 1% 0% 0% 0% 0% -
BALAXI balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 10 11 11 11 11 Reserves 173 190 221 227 238 Borrowings 13 19 53 57 58 Other Liabilities 43 38 25 28 30 Total Liabilities 240 258 310 322 337 Fixed Assets 41 41 41 45 82 CWIP 3 2 22 34 0 Investments 0 0 0 0 0 Other Assets 195 215 247 244 255 Total Assets 240 258 310 322 337
BALAXI cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 34 6 5 -35 -4 Cash from Investing Activity -28 -11 -1 -22 -21 Cash from Financing Activity 0 26 30 34 0 Net Cash Flow 6 21 34 -23 -25 Free Cash Flow 7 -9 4 -57 -25 CFO/OP 78% 32% 26% -98% 3%
BALAXI ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 36 57 84 138 184 Inventory Days 184 189 233 173 202 Days Payable 92 62 82 36 51 Cash Conversion Cycle 129 184 235 275 335 Working Capital Days 92 122 142 186 236 ROCE 60% 37% 21% 13% 3%